Ripple Therapeutics announced today that it entered into a deal with a Bausch + Lomb affiliate related to drug delivery technology. Toronto-based Ripple develops a patented technology platform based on drugs chemically engineered into controlled-release pharmaceuticals without the use of polymers. The proprietary prodrugs undergo surface erosion to give zero-order release kinetics. They are highly […]
Optical/Ophthalmic
Glaukos picks up FDA approval for Epoxia incision-free keratoconus treatment
Glaukos (NYSE:GKOS) announced today that the FDA approved its Epoxia incision-free alternative to traditional corneal cross-linking procedures. Epoxia offers an advancement in corneal cross-linking for the treatment of keratoconus. Glaukos describes the rare, sight-threatening disease as “currently far too often undiagnosed and untreated.” Aliso Viejo, California-based Glaukos developed Epoxia to eliminate the need for the […]
Roche wins CE mark for Susvimo drug-eluting eye implant
Roche announced today that it received CE mark approval for its port delivery platform containing its Susvimo therapeutic. The device, known as Contivue in Europe, comprises the eye implant through which Susvimo is delivered, plus four ancillary devices to initially fill, insert, refill and remove the implant if required. Susvimo (ranibizumab injection) 100 mg/mL remains […]
Gore launches new plunger for prefilled syringes
W.L. Gore today announced the commercial launch of its new 0.5 mL silicone-free Gore ImProject syringe plunger. The new offering, designed specifically for prefilled syringes used in various applications, complements its 1 mL ImProject plunger. According to Gore, its uses extend to areas such as ophthalmic intravitreal injections. Newark, Delaware-based Gore says conventional prefilled syringe […]
SpyGlass Pharma raises $75M for drug delivery platform
SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform. Sands Capital led the financing round, with Gilde Healthcare also joining. Existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC participated. The company said funds support its drug […]
IDE Group launches ophthalmic auto-injector
IDE Group recently unveiled OKO, its new ophthalmic auto-injector for improving drug delivery precision and efficiency. The company says OKO addresses critical unmet needs in ophthalmology. It aims to improve precision, procedural efficiency and patient safety compared to existing adapted injection methods. Currently, intravitreal injections — essential injections for treating retinal diseases like wet age-related […]
SpyGlass Pharma shares positive data for drug-eluting intraocular lens
SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the IOL implant at the time of cataract surgery. The company reported a consistent sustained reduction of intraocular pressure (IOP) across all […]
Clearside Biomedical’s drug-device combo study meets endpoints
Clearside Biomedical (Nasdaq:CLSD) today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary outcomes. Alpharetta, Georgia-based Clearside develops the SCS Microinjector suprachoroidal injection device. It enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to […]
Eyenovia begins manufacturing next-gen drug delivery system
Eyenovia (Nasdaq:EYEN) announced that it began manufacturing batches of its Mydcombi product for its next-generation delivery platform. Manufacturing registration batches of the FDA-approved Mydcombi mydriasis product marks a key step in the approval process for the company’s state-of-the-art Gen-2 Optejet dispensing platform, according to a news release. The company plans to have Mydcombi undergo 12-month […]
Roche, Genentech to reintroduce drug-eluting eye implant in U.S. following 2022 recall
Roche subsidiary Genentech today reintroduced its Susvimo therapy for delivery via ocular implant in the U.S. following a recall. The FDA approved a post-approval supplement to Susvimo’s Biologics License Application (BLA). Approval reflects component-level updates made to the ocular implant and refill needle. Roche now plans to work to make Susvimo available in the U.S. […]
